Janssen submits EMA filing for bladder cancer treatment
Drug Discovery World
SEPTEMBER 14, 2023
“This submission, and Janssen’s ongoing study of erdafitinib, reinforces our commitment to deliver much-needed targeted therapies in the areas of high unmet need, including for devastating diseases like metastatic UC,” said Kiran Patel, Vice President, Clinical Development, Solid Tumours, Janssen Research & Development, LLC.
Let's personalize your content